Browse News
Filter News
Found 170 articles
-
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
4/2/2024
Upstream Bio, a clinical-stage biotech company advancing verekitug for respiratory disorders, announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
-
Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
6/6/2023
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).
-
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
5/11/2023
Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
-
Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel
4/19/2023
Cardurion Pharmaceuticals, Inc. today announced the appointment of Stephen Migausky as Senior Vice President and General Counsel.
-
Latest Updates of 6 Viva's Portfolio Companies
4/4/2023
Recently, 6 of Viva's portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.
-
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
-
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
3/15/2023
Mediar Therapeutics Inc. announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.
-
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
2/23/2023
Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the completion of its previously announced merger.
-
Imara Announces Stockholder Approval of Merger With Enliven
2/22/2023
Imara Inc. announced the results of the special meeting of its stockholders held on February 22, 2023.
-
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
11/3/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, reported business highlights and financial results for the third quarter ended September 30, 2022.
-
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.
-
Versanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles
10/18/2022
Versanis Bio ("Versanis"), a clinical stage company advancing novel therapeutics for people living with obesity and cardiometabolic diseases, today announced two key leadership appointments.
-
Enliven Therapeutics and Imara will merge in an all-stock deal to form a precision oncology company. The new entity will operate under the name Enliven Therapeutics.
-
Enliven Therapeutics and Imara Announce Merger Agreement
10/13/2022
Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference
9/13/2022
On Wednesday morning, September 14th, two dozen advocates from AIDS Healthcare Foundation, the largest global AIDS organization, and its affiliates, Iris House and ACQC will spearhead a protest targeting Gilead Sciences during the annual Baird Global Healthcare Investor Conference being held at the Intercontinental – New York Barclay in New York City.
-
Thryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of Directors
9/1/2022
Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and the addition of Dr. Shi Yin Foo to its Board of Directors.
-
Monkeypox Is an STD, No More Time to Waste, Says AHF
8/18/2022
AIDS Healthcare Foundation (AHF) today is calling for monkeypox to be treated as, and formally classified as a sexually transmitted infection (STI).
-
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
8/15/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imara, and Cynthia Smith, former chief commercial officer of ZS Pharma, to its board of directors.
-
Radiology As A Service Market Size to Exceed US$ 6.7 Bn by 2030
7/12/2022
According to Vision Research Reports, the global Radiology As A Service market size is expected to be worth around US$ 6.7 billion by 2030.
-
Sickle Cell Anemia Therapeutics Market Size, Share, Growth, Trends, Report 2022-2030
7/6/2022
The global Sickle Cell Anemia Therapeutics market size is projected to reach US$ 9388.1 million by 2030, from US$ 3344 million in 2021, at a CAGR of 15.7% during 2022-2030.